ClinicalTrials.gg
CompletedNCT00816842Updated Jan 5, 2009

Plasma Citrulline Concentration in Tropical Enteropathy

An observational study in Malabsorption Syndromes, Granulomatous Enteritis and Enteritis, sponsored by Azienda Ospedaliero-Universitaria di Parma. Completed at 1 site in Zambia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-01-05.

Sponsored by Azienda Ospedaliero-Universitaria di Parma · Observational

Study type
Observational
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood stream. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus will be on the ability of the intestine to sustain the individual concerned from a nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.

Read the detailed description

Preliminary studies reported that plasma citrulline concentrations may be a reliable biochemical marker for intestinal dysfunction and absorptive enterocyte mass. The relationship between citrulline concentration and intestinal function has been supported in other studies including those examining rejection in small bowel allografts. Concentrations of citrulline are dramatically reduced in cases of mucosal damage (e.g. moderate graft rejection or viral enteritis)and strongly correlate (inversely) with severity on biopsy. Plasma citrulline concentration is lower also in patients with villous atrophy (24±13µmol/L)than in healthy subjects (40±10µmol/L)and patients with anorexia nervosa (39±9µmol/L).Experimental studies have been carried out also in assessing the value of citrulline as a marker for severity of small bowel epithelial damage from radiation and viral infections. The plasma citrulline was shown to be a simple, non invasive and sensitive essay to monitor and quantify radiation and/or chemotherapy induced small bowel damage in mice and humans. Otherwise, the literature on citrulline as a potential marker of intestinal and nutritional integrity is young and consistent data for specific conditions as for HIV enteropathy are missing.We hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.

02

Conditions studied

  • Malabsorption Syndromes
  • Granulomatous Enteritis
  • Enteritis
  • HIV Enteropathy
  • Ileal Diseases

Keywords

  • citrulline
  • malabsorption
  • Villous atrophy
  • enteropathy
03

In context

Malabsorption Syndromes

54 studies on the registry are indexed under Malabsorption Syndromes; 12 are open to participants now.

Browse Malabsorption Syndromes studies →

Lead sponsor

Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 44 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Tropical enteropathy with mixed HIV status

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • histologically ascertained Tropical enteropathy
  • Mixed status
  • within normal range

Exclusion criteria

Exclusion Criteria:

  • Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass.
  • Patients with other important disease, which may interfere with the study (especially diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances, which may compromise the patient's ability to comply with the study requirements.
  • Pregnancy
  • Patients experiencing diarrhoea within one month since enrolment date
  • Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or triglycerides
  • Coeliac Disease, Crohn's disease or infectious intestinal disease
  • Patients on or FANS
  • Oral feeding>1.0-fold the estimated basal metabolic rate as assessed using Harris and Benedict equation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

06

What researchers measure

Primary outcomes

  1. postabsorptive plasma citrulline concentration

    Time frame: within two years since enrolment date

Secondary outcomes

  1. intestinal permeability ratio

    Time frame: within two years since enrolment date

07

Study locations

1 site
  • Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital
    Lusaka, Lusaka province P/B RW1X, Zambia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00816842
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
First posted
Jan 5, 2009
Start date
Oct 1998
Primary completion
May 2008
Completion
Sep 2008
Last update
Jan 5, 2009

Study contacts

Cinzia Papadia, MD
principal investigator · Azienda Ospedaliero-Universitaria di Parma
Alastair Forbes, BSc MD FRCP ILTM
study chair · University College London Hospitals
Antonio Di Sabatino, MD
study director · University of Pavia
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion